Project Grant R01AG084596
Award Date
8/15/24
Completion Date
4/30/29
Dollars Obligated
$3.9M
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
The National Institute on Aging (NIA) awarded a $828,534 Cooperative Agreement under the Aging Research federal grant program (CFDA 93.866) to the University of Massachusetts Medical School (UMass Medical) to conduct a molecular dissection of the neuronal-adaptive immune-genomic axis. The goal is to identify novel integrative factors contributing to Alzheimer's disease (AD) pathogenesis or to the protection of brain neurons in the aging process. The project will apply large-scale, innovative,...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $728,370 to The Washington University to develop engineered T cell approaches for Alzheimer's disease. The goal is to design and develop "CARDINAL" (CAR Disease Interventions for Alzheimer's) T cells that are programmed to expand and persist at the site of Alzheimer's pathology, and release neuroprotective payloads such as IL-4 and BDNF to support neuronal function and improve...
The National Institute on Aging (NIA), under its Aging Research Federal Grant Program (CFDA 93.866), awarded Baylor College of Medicine a $2,327,075 project grant (R01AG088197) to investigate the role of the complement pathway and associated signaling molecules in regulating microglia function and their response to amyloid-beta pathology in Alzheimer's disease. The 5-year project aims to delineate the interplay between the complement component C3A, the neuropeptide TLQP-21, and the C3A...
This $614,424 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to better understand the role of microglia, the brain's immune cells, in the development of Alzheimer's disease (AD). The University of Washington (UW) will leverage novel explainable AI techniques and human induced pluripotent stem cell (iPSC) models to uncover subtle microglial changes that occur early in AD progression. Specifically, UW will expose microglia-neuron iPSC cultures to...
This Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) will provide $704,198.00 to Trustees of Dartmouth College from December 1, 2024 to November 30, 2026 to develop chimeric antigen receptor (CAR) T regulatory cells (Tregs) that target aggregated amyloid-beta, a key hallmark of Alzheimer's disease (AD). The goal is to enhance the persistence of these CAR Tregs in the central nervous system to help rebalance cerebral immunity, promote amyloid-beta...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $356,174 to The Regents of the University of California, San Francisco (UCSF) to conduct in vivo testing of structure-based vaccine candidates targeting Alzheimer's disease. The goal is to determine the efficacy of an active immunization strategy in preserving cognitive and neural function by slowing the formation of amyloid-beta or tau protein aggregation in the brain. The research will use...
This Project Grant award from the National Institute on Aging's Aging Research federal grant program (CFDA 93.866) provides $871,419 to the University of Washington to conduct research on the role of microglia, the brain's immune cells, in the pathogenesis of Alzheimer's disease. The research aims to characterize molecular profiles and spatial organization of microglia across the adult age spectrum, both with and without Alzheimer's disease, through single-nucleus RNA sequencing of over 5,000...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will investigate the role of glial fibrillary acidic protein (GFAP) upregulation in reactive astrocytes and its impact on tripartite excitatory synapses in a tauopathy mouse model of Alzheimer's disease. Specifically, the $452,550 award to The General Hospital Corporation (dba Massachusetts General Hospital) will overexpress GFAP in astrocytes and blunt GFAP upregulation to evaluate changes in the...
This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,173,794 to The General Hospital Corporation (Massachusetts General Hospital) to conduct research on enhancing brain resilience to Alzheimer's disease by targeting adult hippocampal neurogenesis. The project aims to explore the mechanisms by which adult hippocampal neurogenesis cooperates with brain-derived neurotrophic factor (BDNF) to potentially slow cognitive decline in...
This Project Grant award of $1,000,000, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by Brigham & Women's Hospital to develop a precision nonviral brain delivery system for CD33-targeting siRNA to treat Alzheimer's disease. The research, conducted in collaboration with Massachusetts General Hospital, aims to characterize novel nanoparticles for efficient delivery of CD33 siRNA to microglia in the brain,...